The Fertility Center of San Antonio Expands Reproductive Services with the Addition of INVOcell
MEDFORD, Mass., Nov. 6, 2018 — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that The Fertility Center of San Antonio, Texas, a leading reproductive services provider in central and southeast Texas, has expanded the scope of its reproductive services with the addition of INVOcell.
Matthew G. Retzloff, M.D., said, “We are pleased to be working with the INVO Bioscience team to add INVOcell to our palette of reproductive services. INVOcell brings innovation to the reproductive services practice by featuring a streamlined process and significant cost benefits to patients. The INVOcell process also decreases the possibility of multiple births, unlike more traditional in-vitro fertilization processes. INVOcell provides an additional avenue of hope to couples that have failed to conceive with other reproductive procedures. We are excited to embrace the benefits of INVOcell for our patients in the greater San Antonio metro area.”
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise be unable to afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.
About the Fertility Center of San Antonio
The Fertility Center of San Antonio has an impressive history that details our commitment to excellence and innovation. We were the first practice to offer office-based in vitro fertilization (IVF) in Texas, and the first to achieve a pregnancy through intracytoplasmic sperm injection (ICSI) in the Southwest. Longevity is one of our defining characteristics. Our Medical Director, Dr. Joseph E. Martin, formed the fertility center over 30 years ago. The fertility doctors at the Fertility Center of San Antonio have over 30 years of experience treating a wide range of fertility issues and have all proudly served our country and are all military veterans. For more information, please visit https://www.fertilitysa.com.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.